Multiple myeloma screening: Difference between revisions
(Mahshid) |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
==Screening== | ==Screening== | ||
There is insufficient evidence to recommend routine screening for multiple myeloma.<ref name="n">Multiple Myeloma Prevention and Screening.(2015)http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/multiple-myeloma/prevention/index.html</ref><ref name="r">Can multiple myeloma be prevented?(2015)http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-prevention</ref> | ===[[Monoclonal gammopathy of undetermined significance]]=== | ||
[[Monoclonal gammopathy of undetermined significance]], or (MGUS), carries a 1% per year risk of progression to active multiple myeloma. Given the risk of progression, patients should be screened via monitoring of [[complete blood count]] and [[serum protein electrophoresis]] (SPEP) typically once yearly. The frequency of screening may vary depending on the MGUS risk group. High-risk patients may need more frequent monitoring. | |||
===[[Smoldering multiple myeloma]]=== | |||
[[Smoldering multiple myeloma]] carries a 10% per year risk of progression to active multiple myeloma. Given the risk of progression, patients should be screened via monitoring of [[complete blood count]] and [[serum protein electrophoresis]] (SPEP) typically once yearly. The frequency of screening may vary depending on the smoldering multiple myeloma risk group. High-risk smoldering multiple myeloma patients may need more frequent monitoring. | |||
===Multiple myeloma=== | |||
There is insufficient evidence to recommend routine screening for active multiple myeloma.<ref name="n">Multiple Myeloma Prevention and Screening.(2015)http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/multiple-myeloma/prevention/index.html</ref><ref name="r">Can multiple myeloma be prevented?(2015)http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-prevention</ref> | |||
==References== | ==References== | ||
Revision as of 05:37, 15 July 2018
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple myeloma screening On the Web |
|
American Roentgen Ray Society Images of Multiple myeloma screening |
|
Risk calculators and risk factors for Multiple myeloma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
There is insufficient evidence to recommend routine screening for multiple myeloma.[1][2]
Screening
Monoclonal gammopathy of undetermined significance
Monoclonal gammopathy of undetermined significance, or (MGUS), carries a 1% per year risk of progression to active multiple myeloma. Given the risk of progression, patients should be screened via monitoring of complete blood count and serum protein electrophoresis (SPEP) typically once yearly. The frequency of screening may vary depending on the MGUS risk group. High-risk patients may need more frequent monitoring.
Smoldering multiple myeloma
Smoldering multiple myeloma carries a 10% per year risk of progression to active multiple myeloma. Given the risk of progression, patients should be screened via monitoring of complete blood count and serum protein electrophoresis (SPEP) typically once yearly. The frequency of screening may vary depending on the smoldering multiple myeloma risk group. High-risk smoldering multiple myeloma patients may need more frequent monitoring.
Multiple myeloma
There is insufficient evidence to recommend routine screening for active multiple myeloma.[1][2]
References
- ↑ 1.0 1.1 Multiple Myeloma Prevention and Screening.(2015)http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/multiple-myeloma/prevention/index.html
- ↑ 2.0 2.1 Can multiple myeloma be prevented?(2015)http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-prevention